tiprankstipranks
Medline, Inc. Class A (MDLN)
NASDAQ:MDLN
US Market
Want to see MDLN full AI Analyst Report?

Medline (MDLN) Stock Forecast & Price Target

270 Followers
See the Price Targets and Ratings of:

MDLN Analyst Ratings

Strong Buy
20Ratings
Strong Buy
18 Buy
2 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Medline
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MDLN Stock 12 Month Forecast

Average Price Target

$52.16
▲(9.48% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Medline in the last 3 months. The average price target is $52.16 with a high forecast of $62.00 and a low forecast of $42.00. The average price target represents a 9.48% change from the last price of $47.64.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"$34","63":"$63","41.25":"$41.3","48.5":"$48.5","55.75":"$55.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$62.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.1578947368421,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,41.25,48.5,55.75,63],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.75,37.76923076923077,39.78846153846154,41.80769230769231,43.82692307692308,45.84615384615385,47.86538461538461,49.88461538461539,51.90384615384615,53.92307692307692,55.94230769230769,57.96153846153846,59.980769230769226,{"y":62,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.75,37.012145748987855,38.27429149797571,39.53643724696356,40.79858299595141,42.06072874493927,43.322874493927124,44.58502024291498,45.847165991902834,47.10931174089069,48.37145748987854,49.63360323886639,50.89574898785425,{"y":52.1578947368421,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.75,36.23076923076923,36.71153846153846,37.19230769230769,37.67307692307692,38.15384615384615,38.63461538461539,39.11538461538461,39.59615384615385,40.07692307692308,40.55769230769231,41.03846153846154,41.51923076923077,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.85,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.75,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.75,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$62.00Average Price Target$52.16Lowest Price Target$42.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG
$55
Buy
15.45%
Upside
Reiterated
06/09/26
Analysts Are Bullish on Top Healthcare Stocks: Medline (MDLN), Danaher (DHR)
William Blair Analyst forecast on MDLN
William Blair
William Blair
Buy
Reiterated
06/03/26
Analyst Initiates Buy on Medline, Citing Attractive 2027 EBITDA Valuation, International Expansion, and Limited Impact from FDA Warning Letter
Robert W. Baird Analyst forecast on MDLN
Robert W. Baird
Robert W. Baird
$45
Buy
-5.54%
Downside
Reiterated
06/02/26
Medline warning letter 'doesn't look great,' says BairdMedline warning letter 'doesn't look great,' says Baird
Barclays
$50$45
Buy
-5.54%
Downside
Assigned
06/01/26
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (NASDAQ: COGT) and Medline (NASDAQ: MDLN)
Tigress Financial Analyst forecast on MDLN
Tigress Financial
Tigress Financial
$60$62
Buy
30.14%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX) and Medline (NASDAQ: MDLN)
Stifel Nicolaus Analyst forecast on MDLN
Stifel Nicolaus
Stifel Nicolaus
$55$50
Buy
4.95%
Upside
Reiterated
05/08/26
Stifel Nicolaus Sticks to Its Buy Rating for Medline (MDLN)
Jefferies Analyst forecast on MDLN
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$53
Buy
11.25%
Upside
Reiterated
05/07/26
Medline (MDLN) Receives a Buy from Jefferies
Bank of America Securities Analyst forecast on MDLN
Bank of America Securities
Bank of America Securities
$55$53
Buy
11.25%
Upside
Reiterated
05/07/26
Medline Maintained at Buy as Analyst Trims Price Target to $53 on Margin Pressures but Highlights Strong Growth Outlook
Morgan Stanley Analyst forecast on MDLN
Morgan Stanley
Morgan Stanley
$52
Buy
9.15%
Upside
Reiterated
05/07/26
Morgan Stanley Sticks to Its Buy Rating for Medline (MDLN)
Deutsche Bank  Analyst forecast on MDLN
Deutsche Bank
Deutsche Bank
$48$42
Hold
-11.84%
Downside
Reiterated
05/07/26
Medline price target lowered to $42 from $48 at Deutsche BankMedline price target lowered to $42 from $48 at Deutsche Bank
TD Cowen
$53
Buy
11.25%
Upside
Reiterated
05/07/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Medline (NASDAQ: MDLN), QuidelOrtho (NASDAQ: QDEL) and Siemens Healthineers AG (Other OTC: SEMHF)
Wells Fargo Analyst forecast on MDLN
Wells Fargo
Wells Fargo
$47
Hold
-1.34%
Downside
Reiterated
05/07/26
Wells Fargo Sticks to Their Hold Rating for Medline (MDLN)
Evercore ISI
$55
Buy
15.45%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Medline (NASDAQ: MDLN), Niagen Bioscience (NASDAQ: NAGE) and BeOne Medicines (NASDAQ: ONC)
Bernstein Analyst forecast on MDLN
Bernstein
Bernstein
$56$54
Buy
13.35%
Upside
Assigned
05/07/26
Medline price target lowered to $54 from $56 at BernsteinMedline price target lowered to $54 from $56 at Bernstein
RBC Capital Analyst forecast on MDLN
RBC Capital
RBC Capital
$53
Buy
11.25%
Upside
Reiterated
05/07/26
RBC Capital Keeps Their Buy Rating on Medline (MDLN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG
$55
Buy
15.45%
Upside
Reiterated
06/09/26
Analysts Are Bullish on Top Healthcare Stocks: Medline (MDLN), Danaher (DHR)
William Blair Analyst forecast on MDLN
William Blair
William Blair
Buy
Reiterated
06/03/26
Analyst Initiates Buy on Medline, Citing Attractive 2027 EBITDA Valuation, International Expansion, and Limited Impact from FDA Warning Letter
Robert W. Baird Analyst forecast on MDLN
Robert W. Baird
Robert W. Baird
$45
Buy
-5.54%
Downside
Reiterated
06/02/26
Medline warning letter 'doesn't look great,' says BairdMedline warning letter 'doesn't look great,' says Baird
Barclays
$50$45
Buy
-5.54%
Downside
Assigned
06/01/26
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (NASDAQ: COGT) and Medline (NASDAQ: MDLN)
Tigress Financial Analyst forecast on MDLN
Tigress Financial
Tigress Financial
$60$62
Buy
30.14%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX) and Medline (NASDAQ: MDLN)
Stifel Nicolaus Analyst forecast on MDLN
Stifel Nicolaus
Stifel Nicolaus
$55$50
Buy
4.95%
Upside
Reiterated
05/08/26
Stifel Nicolaus Sticks to Its Buy Rating for Medline (MDLN)
Jefferies Analyst forecast on MDLN
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$53
Buy
11.25%
Upside
Reiterated
05/07/26
Medline (MDLN) Receives a Buy from Jefferies
Bank of America Securities Analyst forecast on MDLN
Bank of America Securities
Bank of America Securities
$55$53
Buy
11.25%
Upside
Reiterated
05/07/26
Medline Maintained at Buy as Analyst Trims Price Target to $53 on Margin Pressures but Highlights Strong Growth Outlook
Morgan Stanley Analyst forecast on MDLN
Morgan Stanley
Morgan Stanley
$52
Buy
9.15%
Upside
Reiterated
05/07/26
Morgan Stanley Sticks to Its Buy Rating for Medline (MDLN)
Deutsche Bank  Analyst forecast on MDLN
Deutsche Bank
Deutsche Bank
$48$42
Hold
-11.84%
Downside
Reiterated
05/07/26
Medline price target lowered to $42 from $48 at Deutsche BankMedline price target lowered to $42 from $48 at Deutsche Bank
TD Cowen
$53
Buy
11.25%
Upside
Reiterated
05/07/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Medline (NASDAQ: MDLN), QuidelOrtho (NASDAQ: QDEL) and Siemens Healthineers AG (Other OTC: SEMHF)
Wells Fargo Analyst forecast on MDLN
Wells Fargo
Wells Fargo
$47
Hold
-1.34%
Downside
Reiterated
05/07/26
Wells Fargo Sticks to Their Hold Rating for Medline (MDLN)
Evercore ISI
$55
Buy
15.45%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Medline (NASDAQ: MDLN), Niagen Bioscience (NASDAQ: NAGE) and BeOne Medicines (NASDAQ: ONC)
Bernstein Analyst forecast on MDLN
Bernstein
Bernstein
$56$54
Buy
13.35%
Upside
Assigned
05/07/26
Medline price target lowered to $54 from $56 at BernsteinMedline price target lowered to $54 from $56 at Bernstein
RBC Capital Analyst forecast on MDLN
RBC Capital
RBC Capital
$53
Buy
11.25%
Upside
Reiterated
05/07/26
RBC Capital Keeps Their Buy Rating on Medline (MDLN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medline

3 Months
Eric ColdwellRobert W. Baird
Success Rate
2/3 ratings generated profit
67%
Average Return
-3.10%
Copying Eric Coldwell's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of -3.10% per trade.
1 Year
Eric ColdwellRobert W. Baird
Success Rate
1/3 ratings generated profit
33%
Average Return
-9.87%
Copying Eric Coldwell's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -9.87% per trade.
2 Years
Eric ColdwellRobert W. Baird
Success Rate
1/3 ratings generated profit
33%
Average Return
-9.87%
Copying Eric Coldwell's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -9.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDLN Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
1
2
Buy
44
54
33
27
20
Hold
6
7
3
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
50
61
36
31
24
In the current month, MDLN has received 22 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. MDLN average Analyst price target in the past 3 months is 52.16.
Each month's total comprises the sum of three months' worth of ratings.

MDLN Financial Forecast

MDLN Earnings Forecast

The previous quarter’s earnings for MDLN were $0.33.
The previous quarter’s earnings for MDLN were $0.33.

MDLN Sales Forecast

The previous quarter’s earnings for MDLN were $7.35B.
The previous quarter’s earnings for MDLN were $7.35B.

MDLN Stock Forecast FAQ

What is MDLN’s average 12-month price target, according to analysts?
Based on analyst ratings, Medline, Inc. Class A’s 12-month average price target is 52.16.
    What is MDLN’s upside potential, based on the analysts’ average price target?
    Medline, Inc. Class A has 9.48% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MDLN a Buy, Sell or Hold?
          Medline, Inc. Class A has a consensus rating of Strong Buy which is based on 18 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Medline, Inc. Class A’s price target?
            The average price target for Medline, Inc. Class A is 52.16. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $62.00 ,the lowest forecast is $42.00. The average price target represents 9.48% Increase from the current price of $47.64.
              What do analysts say about Medline, Inc. Class A?
              Medline, Inc. Class A’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of MDLN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.